The treatment of osteomyelitis with gentamicin-reconstituted bone xenograft-composite.
We have developed a new drug-delivery system using reconstituted bone xenograft to treat chronic osteomyelitis. This material, which has the capabilities of osteoinduction and osteoconduction, was supplemented with up to 2000 times the minimum inhibitory concentration of gentamicin against Staphylococcus aureus to prepare a gentamicin-reconstituted bone xenograft-composite (G-RBX-C). In a rabbit model, we evaluated the release of gentamicin from this composite in vivo, its capability for induction of ectopic bone and the repair of segmental defects of the radius. There was a high level of concentration of antibiotics, which was sustained for at least ten days. In the study of induction of ectopic bone, there was abundant woven bone in the G-RBX-C group two weeks after operation. At 16 weeks after implantation of G-RBX-C the radial defects had been repaired, with the formation of lamellar bone and recanalisation of the marrow cavity. Our findings suggest that G-RBX-C may be useful in the treatment of chronic osteomyelitis.
Li
X D
XD
Fourth Military Medical University, Xi'an, China.
Hu
Y Y
YY
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016025:Bone Transplantation; D001842:Bone and Bones / Q000293:injuries / Q000601:surgery; D002908:Chronic Disease; D016503:Drug Delivery Systems / Q000379:methods*; D005839:Gentamicins / Q000008:administration & dosage*; D010019:Osteomyelitis / Q000188:drug therapy*; D011817:Rabbits
D000900:Anti-Bacterial Agents; D005839:Gentamicins